GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioArctic AB (STU:B9A) » Definitions » Total Liabilities

BioArctic AB (STU:B9A) Total Liabilities : €12.69 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is BioArctic AB Total Liabilities?

BioArctic AB's Total Liabilities for the quarter that ended in Mar. 2024 was €12.69 Mil.

BioArctic AB's quarterly Total Liabilities increased from Sep. 2023 (€9.60 Mil) to Dec. 2023 (€12.47 Mil) and increased from Dec. 2023 (€12.47 Mil) to Mar. 2024 (€12.69 Mil).

BioArctic AB's annual Total Liabilities declined from Dec. 2021 (€10.62 Mil) to Dec. 2022 (€6.56 Mil) but then increased from Dec. 2022 (€6.56 Mil) to Dec. 2023 (€12.47 Mil).


BioArctic AB Total Liabilities Historical Data

The historical data trend for BioArctic AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioArctic AB Total Liabilities Chart

BioArctic AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 19.93 14.06 10.62 6.56 12.47

BioArctic AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.20 7.93 9.60 12.47 12.69

BioArctic AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BioArctic AB's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=11.172+(0.192+1.107
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=12.47

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=106.032-93.561
=12.47

BioArctic AB's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=11.385+(0.21+1.095
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=12.69

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=100.413-87.723
=12.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioArctic AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of BioArctic AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


BioArctic AB (STU:B9A) Business Description

Traded in Other Exchanges
Address
Warfvinges vag 35, Stockholm, SWE, SE-112 51
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. In addition, the group is also focused on the development of a treatment with a combination of a biodegradable medical device and a drug substance for complete spinal cord injury. Geographically, it derives a majority of its revenue from Asia.

BioArctic AB (STU:B9A) Headlines

No Headlines